On April 27, 2022 Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported the acceptance of two abstracts at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Biomea Fusion, APR 27, 2022, View Source [SID1234613032]). The 2022 ASCO (Free ASCO Whitepaper) annual meeting will be held from June 3-7, 2022, at McCormick Place in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The titles of Biomea’s accepted abstracts are listed below. Biomea will disclose additional information about the presentations in alignment with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s abstract embargo policies.

Accepted 2022 ASCO (Free ASCO Whitepaper) Abstract Titles

Preclinical activity of irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia
COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM)